Figure 2
Figure 2. List of exon 12 NPM1 mutations so far identified in AML patients. Red coloring indicates nucleotides inserted by mutations; green, leucine-rich NES motif; violet, tryptophan (W) residues; L, leucine; C, cysteine; V, valine; M, methionine; and F, phenyl-alanine. Mutations A to F refer to those we originally identified.18 Mutations E to H refer to those we identified in childhood AML.91 Mutations J to Q refer to those subsequently identified in Falini et al.84 Mutations Gm to Qm refer to those we identified in the protocol 99 of the German AML cooperative group.80 Mutations 1, 3, 4, 6, 7, 12, 13, 10, and 14 are according to Dohner et al.81 Mutation I* is according to Verhaak et al.82 *NM_002520. †Mutations G, I, H, and J are according to Suzuki et al.93

List of exon 12 NPM1 mutations so far identified in AML patients. Red coloring indicates nucleotides inserted by mutations; green, leucine-rich NES motif; violet, tryptophan (W) residues; L, leucine; C, cysteine; V, valine; M, methionine; and F, phenyl-alanine. Mutations A to F refer to those we originally identified.18  Mutations E to H refer to those we identified in childhood AML.91  Mutations J to Q refer to those subsequently identified in Falini et al.84  Mutations Gm to Qm refer to those we identified in the protocol 99 of the German AML cooperative group.80  Mutations 1, 3, 4, 6, 7, 12, 13, 10, and 14 are according to Dohner et al.81  Mutation I* is according to Verhaak et al.82  *NM_002520. †Mutations G, I, H, and J are according to Suzuki et al.93 

Close Modal

or Create an Account

Close Modal
Close Modal